September 15, 2015 — Imaging patients soon after a traumatic brain injury (TBI) can lead to more accurate detection of cerebral microhemorrhages, or microbleeding on the brain, according to a study of military service members. Results were published online in the journal Radiology.

More than one in three computed tomography (CT) sites surveyed by The Association for Medical Imaging Management (AHRA) could be subject to a 5 percent reimbursement penalty beginning next year. And that’s the best case. The number could be higher.

In August, when AHRA conducted the survey, 56 percent of respondents indicated they were not in compliance with XR-29, a standard designed to safeguard Medicare patients from excessive CT radiation; 36 percent replied they would not be compliant even by Jan. 1, 2016, the date this standard is scheduled to go into effect.

The current state of proton therapy can be assessed fairly quickly by looking at a map: At the end of 2014, there were 51 proton therapy facilities worldwide, with the United States and Japan accounting for more than half (27) and the rest being scattered around the globe. This suggests there are many cancer patients who may not have easy access to proton therapy — a supposition which turns out to be true, according to Paul-Emmanuel Goethals, co-founder of radiation therapy market analysis firm MEDraysintell.

Vital Images Inc. recently introduced the VioSuite Image Management and Vitality Solutions Business Intelligence product families, providing healthcare administrators with a robust set of tools to improve system-wide image access and image data analytics. VioSuite and Vitality Solutions, as well as the company’s flagship products VitreaAdvanced and VitreaView software, were showcased at the 9th annual Health Information and Management Systems Society (HIMSS) Asia Pacific Conference and Exhibition.

September 14, 2015 — A new decision rule will help emergency department physicians determine when to use radiography in young children with minor head injuries. The Canadian-developed rule is published in the Canadian Medical Association Journal (CMAJ).

Eizo announced it is now offering a white cabinet option for three FlexScan monitors with ultra-slim bezels.

ImaginAb Inc. has released interim results from a Phase 2 clinical trial of IAB2M, the company's proprietary imaging agent for management of prostate cancer. IAB2M demonstrated superior performance in detecting disease compared with ProstaScint and conventional imaging technologies including computed tomography (CT) scans, magnetic resonance imaging (MRI) scans and bone scans. In addition, the agent accurately detected metastatic disease in normal-sized lymph nodes, overcoming a major limitation of existing technologies and addressing a key clinical need.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now